SCHEMBL3305889

SCHEMBL3305889

COc1[c]ccc(S(=O)(=O)N(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.49
LMNA P02545 6/20 0.42
ALDH1A1 P00352 6/20 0.42
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.41
TNF P01375 1/20 0.41
RAB9A P51151 1/20 0.41
NOD1 Q9Y239 1/20 0.41
GAA P10253 1/20 0.39
MAPK1 P28482 1/20 0.39
TSHR P16473 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
VCAM1 P19320 1/20 0.37
POLB P06746 1/20 0.37
PKM P14618 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28247559 0.82 ALDH1A1 (0.54) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL358028 0.80 SMN1; SMN2 (0.46) LMNAALDH1A1SMN1; SMN2MAPK1TSHR
SCHEMBL1459844 0.80 ALDH1A1 (0.41) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL7045277 0.79 ALDH1A1 (0.36) LMNAALDH1A1SMN1; SMN2GAAMAPK1
SCHEMBL26688580 0.77 PSIP1 (0.39) ALDH1A1SMN1; SMN2GAAMEN1KMT2A
SCHEMBL8134166 0.76 TXNRD1 (0.32) MAPK1TSHRPOLB
SCHEMBL10766553 0.75 VCAM1 (0.46) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL7476629 0.75 ALDH1A1 (0.42) LMNAALDH1A1HTTSMN1; SMN2MEN1
SCHEMBL6643093 0.72 MAPT (0.36) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL8129522 0.72 MMP13 (0.38) MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099875-A1 NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS PHOSPHOENIX SARL (FR) 2010-04-22 US claimed
EP-1899358-A2 NOVEL P-CHIRAL FUNCTIONALISED ARYLPHOSPHINES AND DERIVATIVES, THE PREPARATION AND USE THEREOF FOR ASYMMETRICAL CATALYSIS Phosphoenix SARL (FR) 2008-03-19 EP claimed
WO-2006136695-A2 NOVEL P-CHIRAL FUNCTIONALISED ARYLPHOSPHINES AND DERIVATIVES, THE PREPARATION AND USE THEREOF FOR ASYMMETRICAL CATALYSIS PHOSPHOENIX SARL (FR) 2006-12-28 WO claimed
US-20100099875-A1 NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS PHOSPHOENIX SARL (FR) 2010-04-22 US disclosed
EP-1899358-A2 NOVEL P-CHIRAL FUNCTIONALISED ARYLPHOSPHINES AND DERIVATIVES, THE PREPARATION AND USE THEREOF FOR ASYMMETRICAL CATALYSIS Phosphoenix SARL (FR) 2008-03-19 EP disclosed
WO-2006136695-A2 NOVEL P-CHIRAL FUNCTIONALISED ARYLPHOSPHINES AND DERIVATIVES, THE PREPARATION AND USE THEREOF FOR ASYMMETRICAL CATALYSIS PHOSPHOENIX SARL (FR) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099875-A1 NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS PNP, NANP, PHOSPHO1 MAPT 4766/4885LMNA 4735/4885ALDH1A1 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.